Paper Details

  1. Home
  2. Paper Details

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.

Author: , ArenasJ, CallejaJ L, CarriónJ A, CrespoJ, DelgadoM, FernándezI, FernándezJ R, Fernández-RodríguezC, García-ParedesF, García-SamaniegoJ, HermoJ A, HerreroJ I, JorqueraF, LensS, LlanerasJ, Lázaro RíosM, MacíasM, MorenoJ M, MorillasR M, PascasioJ M, PerellóC, PorresJ C, PrietoM, RealY, RincónD, RodríguezM, RuizP, Ruiz-AntoránB, SerraM Á, TurnesJ

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effectiveness and safety of a combination therapy for hepatitis C virus (HCV) infection in clinical practice. The study found that ombitasvir/paritaprevir/ritonavir±dasabuvir was highly effective in achieving sustained virological response (SVR), with a 96.2% success rate. While serious adverse events (SAEs) were reported in 10.3% of patients, the therapy was generally well tolerated.
Paper Details　
Original Abstract of the Article :
Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.12637

データ提供：米国国立医学図書館（NLM）

Hepatitis C: A Journey Towards Viral Eradication

My research often leads me to the fascinating world of [virology], where scientists are constantly seeking new ways to combat [viral infections]. This study investigates the effectiveness and safety of a new combination therapy, [ombitasvir/paritaprevir/ritonavir±dasabuvir], for the treatment of [chronic hepatitis C virus (HCV) infection]. Researchers analyzed data from an early access program in Spain to assess the treatment outcomes and safety profile of this new therapy.

A Promising Oasis in the Desert of HCV

The study found that [ombitasvir/paritaprevir/ritonavir±dasabuvir] was highly effective in achieving [sustained virologic response (SVR)] in patients with [genotype 1 or 4 HCV infection]. The SVR rates were impressive, with a [96.2% success rate], demonstrating the potential of this combination therapy to effectively treat HCV infection.

Fighting the Virus: The Importance of Comprehensive Treatment

Imagine a caravan traversing a desert, facing a multitude of challenges like thirst, heat, and potential encounters with wild animals. Similarly, patients with HCV infection face a complex journey, battling the virus and its potential complications. This research highlights the importance of comprehensive treatment strategies, like the use of [ombitasvir/paritaprevir/ritonavir±dasabuvir], to effectively manage HCV infection and improve patients' lives.

Dr.Camel's Conclusion

This study provides encouraging evidence for the effectiveness and safety of [ombitasvir/paritaprevir/ritonavir±dasabuvir] in treating HCV infection. The high SVR rates achieved in this study offer hope for patients with HCV, suggesting a potential path towards viral eradication. Just as a camel can find its way across a challenging desert, we can continue to develop innovative treatments to overcome the challenges posed by viral infections.

Date :
  1. Date Completed 2018-01-02
  2. Date Revised 2018-06-15
Further Info :

Pubmed ID

27976491

DOI: Digital Object Identifier

10.1111/jvh.12637

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.